CAR T-cell Therapy JCAR017 Shows Sustained Anticancer Response in Aggressive B-Cell Lymphoma, Trial Update … – Lymphoma News Today
Lymphoma News Today |
CAR T-cell Therapy JCAR017 Shows Sustained Anticancer Response in Aggressive B-Cell Lymphoma, Trial Update …
Lymphoma News Today Treatment with the CAR T-cell therapy JCAR017 (lisocabtagene maraleucel, or liso-cel) provided a durable reduction or eradication of cancer in patients with aggressive forms of B-cell non-Hodgkin's lymphoma (NHL), long-term data from a Phase 1 trial … |
